Of the four biotech IPOs that were scheduled to price this week, only two priced successfully. These were the first two biotech IPOs in almost a month, both of which had heavy insider buying.
...read more
Intellia Therapeutics, a preclinical biotech developing gene editing therapies using CRISPR/Cas9 technology, raised $108 million by offering 6 million shares at $18, the high end of the range of $16 to $18. Intellia Therapeutics plans to list on the Nasdaq under the symbol NTLA. Credit Suisse, Jefferies and Leerink Partners acted as lead managers on the deal....read more
After seven IPOs in a row outside the healthcare sector, four biotechs will attempt to price their IPOs in the week ahead, all with insider support. Looking more broadly, the next two weeks could see an increased number of launches if companies in the pipeline wish to complete their deals before the Memorial Day...read more
Intellia Therapeutics, a preclinical biotech developing gene editing therapies using CRISPR/Cas9 technology, announced terms for its IPO on Wednesday. The Cambridge , MA-based company plans to raise $85 million by offering 5 million shares at a price range of $16 to $18. Insiders intend to purchase $30 million worth of shares in the offering. At the midpoint of the proposed...read more
IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
US IPO Weekly Recap: Biotechs get pushback, but gene editing still soars
Of the four biotech IPOs that were scheduled to price this week, only two priced successfully. These were the first two biotech IPOs in almost a month, both of which had heavy insider buying. ...read more
Intellia Therapeutics prices upsized IPO at $18, the high end of the range
Intellia Therapeutics, a preclinical biotech developing gene editing therapies using CRISPR/Cas9 technology, raised $108 million by offering 6 million shares at $18, the high end of the range of $16 to $18. Intellia Therapeutics plans to list on the Nasdaq under the symbol NTLA. Credit Suisse, Jefferies and Leerink Partners acted as lead managers on the deal....read more
Week ahead: Biotechs Strike Back with Four IPOs
After seven IPOs in a row outside the healthcare sector, four biotechs will attempt to price their IPOs in the week ahead, all with insider support. Looking more broadly, the next two weeks could see an increased number of launches if companies in the pipeline wish to complete their deals before the Memorial Day...read more
Gene editing biotech Intellia Therapeutics sets terms for $85 million IPO
Intellia Therapeutics, a preclinical biotech developing gene editing therapies using CRISPR/Cas9 technology, announced terms for its IPO on Wednesday. The Cambridge , MA-based company plans to raise $85 million by offering 5 million shares at a price range of $16 to $18. Insiders intend to purchase $30 million worth of shares in the offering. At the midpoint of the proposed...read more